Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03548818 · ClinicalTrials.gov registry record
Role of Interferon-gamma 1-b (IFN-γ) on Cells of the Innate Immune System: Functional, Biochemical and Gene Expression Studies in Patients With Chronic Granulomatous Disease
A clinical trial, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- 9
- Enrollment target
NCT03548818: Completed study, sponsored by University of Colorado, Denver.
NCT03548818 is a clinical trial that has completed, run by University of Colorado, Denver. The registered enrollment target is 9 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03548818 has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- 9 participants
- Enrollment target
Study Summary
The overall goal of the study is to investigate the functional, biochemical, and gene expression effects of Interferon-gamma 1-b (IFN-γ) on the neutrophils of patients with Chronic Granulomatous Disease (CGD). The investigators hypothesize that the clinical effects demonstrated in patients with CGD treated with IFN-γ (decreased number and severity of infections) are the result of biochemical processes and upregulation of specific genes, which lead to enhanced functionality of this immune cell population.
Primary Outcome
Determine changes in neutrophil function in neutrophils from patients with CGD
Interventions
- DRUG Interferon Gamma-1B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2018-05-16 |
| Est. Completion | 2020-07-15 |
What the finished NCT03548818 record still lists
NCT03548818 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 9 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Interferon Gamma-1B is the first listed.
NCT03548818 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03548818 about?
NCT03548818 is a clinical study titled "Role of Interferon-gamma 1-b (IFN-γ) on Cells of the Innate Immune System: Functional, Biochemical and Gene Expression Studies in Patients With Chronic Granulomatous Disease". The overall goal of the study is to investigate the functional, biochemical, and gene expression effects of Interferon-gamma 1-b (IFN-γ) on the neutrophils of patients with Chronic Granulomatous Disease (CGD). The investigators hypothesize that the clinical effects demonstrated in patients with CGD ...
What is the current status of trial NCT03548818?
This trial is currently completed. The enrollment target is 9 participants. The study started on 2018-05-16. Estimated completion is 2020-07-15.
What interventions are being tested in trial NCT03548818?
The interventions under investigation include: Interferon Gamma-1B (DRUG).
Who is sponsoring clinical trial NCT03548818?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI